Trending...
- Need some Comic Relief from all the Political Ads? Check out a Poem and a Song called RUN FOR OFFICE
- BAG FUEL Live Announces high profile MLK Weekend Event at NYC'S Legendary S.O.B.'S
- Award-Winning USAF Band of Mid-America Announces Tennessee Concert Series
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involving prescription fentanyl patches
ORLANDO, Fla. - eMusicWire -- The fentanyl crisis remains one of America's most serious public-health challenges. While recent national data show meaningful improvement, the scale of the problem remains enormous. According to the CDC, 47,735 U.S. overdose deaths in 2024 involved synthetic opioids other than methadone, a category that includes fentanyl and fentanyl analogs.
Importantly, there are two very different fentanyl problems. Illicitly manufactured fentanyl is responsible for the majority of fentanyl-related harms, while pharmaceutical fentanyl remains an important medication used for severe pain. The CDC notes that pharmaceutical fentanyl can be prescribed in transdermal patches and that those patches can be diverted for misuse.
That second issue is where Nutriband Inc. (N A S D A Q: NTRB) $NTRB is attempting to make a difference.
AVERSA™: Targeting Abuse and Accidental Exposure
Nutriband's lead development program is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl system designed to incorporate Nutriband's proprietary AVERSA™ technology into a fentanyl patch.
The company's technology is intended to incorporate aversive agents into transdermal patches to help deter abuse, misuse, diversion and accidental exposure while maintaining access to the medication for patients who legitimately require it.
That distinction is critical.
Nutriband is not claiming to solve the illicit fentanyl crisis by itself. Instead, its potential contribution is focused on improving the safety profile of legitimate pharmaceutical transdermal medications that contain fentanyl or other drugs with abuse potential.
More on eMusic Wire
And that could address a meaningful, preventable portion of fentanyl-related harm.
A Look Inside America's Fentanyl Crisis
A new video examining the fentanyl crisis across the United States also features Nutriband CEO Gareth Sheridan.
The video's description explains:
"In this video I travel across the United States to investigate the fentanyl crisis that is destroying major cities across America. I speak with journalist and fentanyl researchers like Gareth Sheridan (CEO of Nutriband) to discover what is taking place in each major city from Portland, Seattle, LA and Philadelphia."
Watch the Fentanyl Crisis Investigation Featuring Gareth Sheridan
The appearance provides another opportunity for Sheridan to discuss the broader fentanyl problem and Nutriband's approach to improving the safety of prescription transdermal fentanyl.
Why This Matters for NTRB
The potential significance of AVERSA™ goes beyond simply creating another fentanyl patch.
Nutriband has designed the technology as a platform, meaning AVERSA™ could potentially be incorporated into multiple transdermal medications with abuse potential.
The company has previously reported that its AVERSA™ technology is protected by an international intellectual-property portfolio, while AVERSA™ Fentanyl remains its lead development program. Nutriband has estimated potential peak annual U.S. sales of approximately $80 million to $200 million for the product, although that is a company estimate and not a guarantee of future sales.
The development program is also moving through the regulatory pathway. Nutriband reported completing a Type C meeting with the FDA concerning Chemistry, Manufacturing and Controls plans for AVERSA™ Fentanyl, with the company working toward an IND filing supporting a Human Abuse Potential study.
More on eMusic Wire
More recently, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said that, once allowed, it plans to submit the commercial worldwide brand name to the FDA and other international regulatory agencies.
A Different Kind of Fentanyl Opportunity
For NTRB investors, the larger story is not that Nutriband can eliminate America's fentanyl crisis. No single technology can do that.
The more specific opportunity is whether AVERSA™ can make legitimate transdermal fentanyl safer by reducing the potential for abuse, diversion and accidental exposure.
With fentanyl continuing to represent a major component of America's overdose crisis, technologies designed to reduce preventable harm remain highly relevant.
Nutriband $NTRB is attempting to bring a different tool to that fight — one focused not on illicit fentanyl itself, but on making pharmaceutical transdermal fentanyl potentially safer for patients, families and communities.
That makes the continued development of AVERSA™ Fentanyl an important story to watch as Nutriband moves toward its next regulatory and commercialization milestones.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Importantly, there are two very different fentanyl problems. Illicitly manufactured fentanyl is responsible for the majority of fentanyl-related harms, while pharmaceutical fentanyl remains an important medication used for severe pain. The CDC notes that pharmaceutical fentanyl can be prescribed in transdermal patches and that those patches can be diverted for misuse.
That second issue is where Nutriband Inc. (N A S D A Q: NTRB) $NTRB is attempting to make a difference.
AVERSA™: Targeting Abuse and Accidental Exposure
Nutriband's lead development program is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl system designed to incorporate Nutriband's proprietary AVERSA™ technology into a fentanyl patch.
The company's technology is intended to incorporate aversive agents into transdermal patches to help deter abuse, misuse, diversion and accidental exposure while maintaining access to the medication for patients who legitimately require it.
That distinction is critical.
Nutriband is not claiming to solve the illicit fentanyl crisis by itself. Instead, its potential contribution is focused on improving the safety profile of legitimate pharmaceutical transdermal medications that contain fentanyl or other drugs with abuse potential.
More on eMusic Wire
- Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
- Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
And that could address a meaningful, preventable portion of fentanyl-related harm.
A Look Inside America's Fentanyl Crisis
A new video examining the fentanyl crisis across the United States also features Nutriband CEO Gareth Sheridan.
The video's description explains:
"In this video I travel across the United States to investigate the fentanyl crisis that is destroying major cities across America. I speak with journalist and fentanyl researchers like Gareth Sheridan (CEO of Nutriband) to discover what is taking place in each major city from Portland, Seattle, LA and Philadelphia."
Watch the Fentanyl Crisis Investigation Featuring Gareth Sheridan
The appearance provides another opportunity for Sheridan to discuss the broader fentanyl problem and Nutriband's approach to improving the safety of prescription transdermal fentanyl.
Why This Matters for NTRB
The potential significance of AVERSA™ goes beyond simply creating another fentanyl patch.
Nutriband has designed the technology as a platform, meaning AVERSA™ could potentially be incorporated into multiple transdermal medications with abuse potential.
The company has previously reported that its AVERSA™ technology is protected by an international intellectual-property portfolio, while AVERSA™ Fentanyl remains its lead development program. Nutriband has estimated potential peak annual U.S. sales of approximately $80 million to $200 million for the product, although that is a company estimate and not a guarantee of future sales.
The development program is also moving through the regulatory pathway. Nutriband reported completing a Type C meeting with the FDA concerning Chemistry, Manufacturing and Controls plans for AVERSA™ Fentanyl, with the company working toward an IND filing supporting a Human Abuse Potential study.
More on eMusic Wire
- Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
- Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
- Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
- After Asheville's Record Rain, KayeDinero Drops "Hathor-Sekhmet" and Marks Copyright Milestone
- Service Guys Urges Ontario Homeowners to Book Chimney Cleaning and WETT Inspections Before the 2026 Heating Season
More recently, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said that, once allowed, it plans to submit the commercial worldwide brand name to the FDA and other international regulatory agencies.
A Different Kind of Fentanyl Opportunity
For NTRB investors, the larger story is not that Nutriband can eliminate America's fentanyl crisis. No single technology can do that.
The more specific opportunity is whether AVERSA™ can make legitimate transdermal fentanyl safer by reducing the potential for abuse, diversion and accidental exposure.
With fentanyl continuing to represent a major component of America's overdose crisis, technologies designed to reduce preventable harm remain highly relevant.
Nutriband $NTRB is attempting to bring a different tool to that fight — one focused not on illicit fentanyl itself, but on making pharmaceutical transdermal fentanyl potentially safer for patients, families and communities.
That makes the continued development of AVERSA™ Fentanyl an important story to watch as Nutriband moves toward its next regulatory and commercialization milestones.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on eMusic Wire
- Kardinal Guitars Introduces the Kardinal Bass
- Steinway Piano Gallery of Kansas City Extends Store Closing Event
- Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
- BAG FUEL Live Announces high profile MLK Weekend Event at NYC'S Legendary S.O.B.'S
- netElastic Announces vBNG And CGNAT 2.0 General Availability
- From Twisters to Trees: NTSO Opens 23rd Season with "Nature"
- Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
- Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
- Award-Winning USAF Band of Mid-America Announces Tennessee Concert Series
- NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
- After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
- Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
- Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
- Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
- Hunter Is Releasing New Music For The Holidays!
- Tixpool.com - Naija Premier Event Reseller
- Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
- The Origin and Evolution of RonDoe Midnight Halls
- Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity